N-Salicyloyltryptamine

N-Salicyloyltryptamine acts on voltage-dependent Na+, Ca2+, and K+ ion channels inhibitor. N-Salicyloyltryptamine inhibits K+ currents with an IC50 value of 34.6 μM (Ito) . N-Salicyloyltryptamine also exhibits anticonvulsant, anti-inflammatory, analgesic, and vasorelaxation effect[1]-[5].

Product Specifications

CAS Number

[31384-98-2]

UNSPSC

12352005

Hazard Statement

H302, H315, H319, H335

Target

Calcium Channel; ERK; Guanylate Cyclase; NF-κB; Potassium Channel

Type

Reference compound

Related Pathways

GPCR/G Protein; MAPK/ERK Pathway; Membrane Transporter/Ion Channel; Neuronal Signaling; NF-κB; Stem Cell/Wnt

Applications

COVID-19-immunoregulation

Field of Research

Inflammation/Immunology; Neurological Disease; Cardiovascular Disease

Assay Protocol

https://www.medchemexpress.com/n-salicyloyltryptamine.html

Purity

96.37

Solubility

DMSO : 125 mg/mL (ultrasonic)

Smiles

OC1=C(C(NCCC2=CNC3=C2C=CC=C3)=O)C=CC=C1

Molecular Formula

C17H16N2O2

Molecular Weight

280.32

Precautions

H302, H315, H319, H335

References & Citations

[1]Gasparotto J, et al Effect of N-salicyloyltryptamine (STP), a novel tryptamine analogue, on parameters of cell viability, oxidative stress, and immunomodulation in RAW 264.7 macrophages. Cell Biol Toxicol. 2013 Jun;29 (3) :175-87. |[2]Araújo DA, et al. N-salicyloyltryptamine, a new anticonvulsant drug, acts on voltage-dependent Na+, Ca2+, and K+ ion channels. Br J Pharmacol. 2003 Dec;140 (7) :1331-9. |[3]Veras RC, et al. N-Salicyloyltryptamine, an N-Benzoyltryptamine Analogue, Induces Vasorelaxation through Activation of the NO/sGC Pathway and Reduction of Calcium Influx. Molecules. 2018 Jan 28;23 (2) :253. |[4]Oliveira FA, et al. Anticonvulsant properties of N-salicyloyltryptamine in mice. Pharmacol Biochem Behav. 2001 Feb;68 (2) :199-202. |[5]Quintans LJ Jr, et al. Bioassay-guided evaluation of antinociceptive effect of N-salicyloyltryptamine: a behavioral and electrophysiological approach. J Biomed Biotechnol. 2010;2010:230745.